INFINITY PHARMACEUTICALS, INC. Infinity Pharmaceuticals, Inc. Share Price
Equities
INFI.Q
US45665G3039
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | 0.00% |
|
0.00% | -99.96% |
| 03-25 | North American Morning Briefing : Tech in Focus on -2- | DJ |
| 03-25 | Infinity Pharmaceuticals, Inc. Went Out of Business | CI |
| Sales 2021 | 1.86M 149M | Sales 2022 | 2.59M 208M | Capitalization | 49.59M 3.97B |
|---|---|---|---|---|---|
| Net income 2021 | -45M -3.6B | Net income 2022 | -44M -3.52B | EV / Sales 2021 | 91.8 x |
| Net cash position 2021 | 29.67M 2.37B | Net Debt 2022 | 11.04M 883M | EV / Sales 2022 | 23.4 x |
| P/E ratio 2021 |
-4.25
x | P/E ratio 2022 |
-1.11
x | Employees | 30 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 97.27% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 3 months | -99.00% | ||
| 6 months | -99.98% | ||
| Current year | -99.96% |
1 month
0.00
0.00
Current year
0.000.02
1 year
0.000.26
3 years
0.003.89
5 years
0.005.98
10 years
0.0018.25
| Managers | Title | Age | Since |
|---|---|---|---|
Seth Tasker
CEO | Chief Executive Officer | 45 | 29/02/08 |
Jennifer Roberts
PRN | Corporate Officer/Principal | - | 30/09/17 |
Melissa Hackel
PRN | Corporate Officer/Principal | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anthony Evnin
BRD | Director/Board Member | 83 | 31/08/06 |
Norman Selby
BRD | Director/Board Member | 71 | 11/03/12 |
David W. Beier
BRD | Director/Board Member | 75 | 31/03/18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.000001 | 0.00% | 1,350 |
| 22/04/24 | 0.000001 | 0.00% | 100 |
End-of-day quote OTC Markets, April 25, 2024
More quotes
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing medicines for people with cancer. The Company is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase I/Ib clinical study.
| 1st Jan change | Capi. | |
|---|---|---|
| -99.96% | 90 | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- INFI.Q Stock
